title: Efficacy and safety of combined treatment with pegylated-IFN-alpha 2b plus ribavirin in HIV-hepatitis C virus-co-infected patients.
authors.forename: Roberta
authors.initials: R
authors.lastname: Cinelli
authors.forename: Giampiero
authors.initials: G
authors.lastname: Di Gennaro
authors.forename: Guglielmo
authors.initials: G
authors.lastname: Nasti
authors.forename: Rosamaria
authors.initials: R
authors.lastname: Tedeschi
authors.forename: Luigino
authors.initials: L
authors.lastname: Dal Maso
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Canzonieri
authors.forename: Luca
authors.initials: L
authors.lastname: Balestreri
authors.forename: Paola
authors.initials: P
authors.lastname: Fedele
authors.forename: Umberto
authors.initials: U
authors.lastname: Tirelli
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a